Histapp

Quick links to important sections

Histapp

Method of action: Antitussive

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Histapp

Property Description
Active Ingredients Brompheniramine, Pseudoephedrine
Form Tablets, Capsules, Oral Liquid
Pharmacological Class Antihistamine/Decongestant Combination
General Purpose Symptomatic relief of allergic rhinitis and cold symptoms
Origin Synthetic

What Type of Medicine is Histapp?

Histapp is a combination medication classified pharmacologically as an Antihistamine/Decongestant Combination, formulated for the temporary relief of symptoms associated with upper respiratory conditions, such as the common cold and allergic rhinitis. It is a synthetic pharmaceutical preparation typically administered via the oral route, commonly available in dosage forms including tablets, capsules (often as extended-release preparations to sustain relief), and oral liquid (syrup). This established formulation is clinically recognized for simultaneously managing both nasal congestion and allergic rhinitis symptoms.


Composition and Origin: The Dual-Action Formula

The drug is composed of two primary active ingredients: Brompheniramine maleate and Pseudoephedrine hydrochloride. Brompheniramine is the antihistamine component, belonging to the alkylamine class and specifically functioning as a first-generation H1 receptor antagonist. Pseudoephedrine, the secondary component, is classified as a sympathomimetic amine that acts as a potent nasal decongestant. The dual action of this combination is its distinctive feature, contrasting with single-ingredient products. The manufacturing profile often emphasizes the extended-release capability of the solid forms, which provides a predictable duration of action, a property that is pharmacologically supported by its dissolution profile.


General Purpose: Targeting Allergic and Cold Symptoms

The general purpose of Histapp is to alleviate discomfort by simultaneously reducing the effects of an allergic reaction and clearing nasal blockage. The antihistamine action controls symptoms such as continuous runny nose and frequent sneezing by reducing the impact of the naturally occurring substance histamine. Concurrently, the decongestant action works by causing vasoconstriction, the narrowing of blood vessels in the nasal membranes, to shrink swollen tissues, thereby relieving nasal congestion and associated sinus pressure. This dual approach provides comprehensive relief, such as in the typical scenario of reducing night-time congestion and sneezing associated with seasonal hay fever.

Regulatory References

  1. DailyMed (National Institutes of Health)

What side effects are possible with Histapp?

Histapp's official safety profile and documented adverse reactions are categorized according to governmental regulatory standards, reflecting the properties of its antihistamine and decongestant components.

Frequency and System-Organ Classifications

Official labeling classifies certain effects as the Most Frequent Adverse Reactions. These typically involve the Nervous System Disorders and Anticholinergic Effects, including drowsiness/somnolence, dizziness, and dryness of the mouth, nose, and throat, as well as thickening of bronchial secretions. Other reactions are documented across various System-Organ-Classes, such as Gastrointestinal Disorders (e.g., nausea, constipation) and Cardiovascular System Disorders (e.g., palpitations, changes in blood pressure).

Serious Adverse Reactions and Population-Specific Safety

Regulatory documents highlight the potential for certain serious adverse reactions, including convulsions, hallucinations, and severe hypersensitivity reactions. Rare, but documented, effects also include Hematologic Disorders like hemolytic anemia and agranulocytosis.

Specific Population-Specific Safety Considerations are noted in official labeling. Pediatric patients may exhibit paradoxical effects such as excitation or restlessness, rather than sedation. Older adults may show increased sensitivity to the medication, specifically regarding dizziness, sedation, confusion, and adverse effects on heart rate or blood pressure.

Safety-Related Restrictions

Use of this medication is subject to documented restrictions. It is restricted from use in individuals with severe hypertension or severe coronary artery disease. It is also constrained by an official warning regarding concurrent or recent use (within 14 days) of Monoamine Oxidase Inhibitors (MAOIs). The documented safety data formally structures the risk profile around these specific neurological, cardiovascular, and anticholinergic concerns.

Overdose and Emergency Response

Overdose and when to seek help

Overdose involving Histapp (Brompheniramine/Pseudoephedrine) carries the potential for severe or life-threatening outcomes and requires immediate medical attention. Official regulatory documents describe a spectrum of manifestations affecting major physiological systems. Symptoms may include contradictory central nervous system (CNS) effects, ranging from profound depression (somnolence, coma) to severe stimulation (agitation, tremor, convulsions). Cardiovascular signs include tachycardia, palpitations, hypertension, and the potential for cardiac arrhythmias. Anticholinergic effects such as mydriasis, fever (hyperpyrexia), and urinary retention are also officially documented.

The official profile lists cardiorespiratory collapse and circulatory failure as potential severe outcomes. Due to these risks, any suspicion of overdose requires individuals to contact emergency medical services or a Poison Control Center immediately, as mandated by regulatory guidance. Treatment is officially specified as symptomatic and supportive. Continuous cardiac monitoring (ECG/EGG) and measures like the administration of activated charcoal are described procedures. Regulatory information notes increased severity and risk of CNS stimulation in pediatric patients, and increased susceptibility in the elderly. No specific antidote is known for this combination.

Therapeutic Uses of Histapp

What Histapp Treats: Main Uses and Benefits

Histapp is generally considered relevant for symptomatic support in managing the effects of dietary histamine intolerance (HIT). The product is relevant in conditions presenting with systemic or localized discomfort and symptoms related to systemic imbalance. In contexts marked by increased discomfort or tension, taking DAO supplements may be part of symptomatic management to help provide supportive relief when symptoms interfere with routine activities. It is applied across domains where additional symptomatic support is needed, addressing symptom clusters that may become intense or disruptive.

Quick Fact: Relief for Episodic Distress

Histapp is applied when patients experience temporary, disruptive symptoms that interfere with daily comfort, allowing them to better manage these specific symptomatic periods.

Commonly, Histapp is used to help with symptom clusters related to physical discomfort, systemic imbalance, and symptoms of increased neurological activity. It is particularly relevant during phases when symptoms become more noticeable after consuming specific foods. It contributes to easing the overall symptom load and may help patients cope more steadily with symptom fluctuations.

Summary of Indications

Histapp is relevant for easing symptoms that interfere with daily comfort, focusing on symptom clusters related to physical discomfort and heightened physiological activity. This is applied in addressing symptoms related to physical discomfort, symptoms related to systemic imbalance, and symptoms of increased neurological activity.

Eligibility and Restrictions for Use

Histapp (Brompheniramine/Pseudoephedrine) eligibility is strictly defined by regulatory authorities and is based on age, physiological status, and underlying medical conditions.

Absolute Contraindications (Must Not Use)

Population/Condition Regulatory Status
Newborns or Premature Infants Contraindicated
Nursing Mothers Contraindicated
Severe Hypertension Contraindicated
Severe Coronary Artery Disease Contraindicated
Concurrent MAOI Therapy Contraindicated
Severe Renal Impairment Contraindicated

Use Restrictions and Cautions

The medicine may be used under standard labeled conditions by adults and adolescents 12 years of age and older. Use in children under 6 years of age is generally not recommended as safety and effectiveness have not been established.

Caution is required in populations with specific comorbidities, including diabetes mellitus, hyperthyroidism, narrow angle glaucoma, and conditions causing urinary retention. Older adults (65+ years) should use the medicine cautiously due to a higher risk of adverse reactions. During pregnancy, Histapp is classified as Category C and is not recommended during the first trimester or the last two weeks.

What should I know about interactions with other medicines?

The official interaction profile for Histapp, a combination of Brompheniramine and Pseudoephedrine, is defined by several mandatory restrictions and warnings rooted in pharmacodynamic principles.

Interaction Classifications

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is a strictly contraindicated combination. Regulatory labeling specifies that Histapp must not be used within 14 days of stopping MAOI therapy. This restriction is necessary because MAOIs prolong and intensify the anticholinergic effects of Brompheniramine and may enhance the effects of the sympathomimetic component, Pseudoephedrine.

Official Interaction Statements

A second major documented interaction involves Central Nervous System (CNS) Depressants, including hypnotics, sedatives, tranquilizers, and antianxiety agents. The Brompheniramine component has additive effects with these medicines, a pharmacodynamic interaction that results in enhanced CNS depression.

The Pseudoephedrine component is documented to reduce the effects of certain Antihypertensive Drugs, which establishes an opposing pharmacological action. Official labeling further advises limiting the use of substances like alcohol and products containing caffeine, due to the risk of additive CNS depression or potential interaction with the decongestant's stimulating effects. These documented constraints classify the use of Histapp with other agents.

Mechanism of Action

Histapp functions as an exogenous diamine oxidase (DAO) enzyme supplement. The DAO enzyme is primarily localized in the brush border of the intestinal mucosa. Upon oral administration, Histapp is directed into the gastrointestinal tract, where it acts locally within the lumen. Its specific biological target is ingested histamine present in the digestive tract. The interaction type is enzymatic degradation.

DAO catalyzes the oxidative deamination of the histamine molecule, converting it into an inactive imidazole-acetaldehyde metabolite. This molecular process effectively reduces the concentration of histamine available for absorption across the intestinal epithelium and subsequent systemic circulation. The intracellular pathway consequences involve a reduced load on the endogenous histamine metabolic capacity. Downstream cascade modulation includes a decrease in the systemic histamine pool, thereby mitigating histamine-mediated signaling through peripheral histamine receptors (H1, H2, H3, H4). The system-level physiological consequence is a reduction in the total circulating level of the biogenic amine.

Dosage and Administration Information

How to Use Histapp

This section outlines the high-level principles for the administration and dosing of Histapp (Brompheniramine/Pseudoephedrine).


Administration and Dosing Principles

The approved route of administration for Histapp is exclusively oral (by mouth). The medication is available in several dosage forms, including immediate-release tablets and capsules, oral liquid (syrup), and specialized extended-release (ER) forms.

Standard adult and adolescent dosing (age 12 and older) is structured around two main patterns: immediate-release (IR) forms are typically taken every 4 to 6 hours as needed, while extended-release forms are designed for dosing every 12 hours or once daily, depending on the specific strength. It is a fundamental usage constraint that the total daily intake must not exceed the maximum label-specified limits, which are 24 mg for Brompheniramine and 240 mg for Pseudoephedrine in a 24-hour period.

Contextual Use and Procedural Requirements

For practical administration, Histapp can be taken with or without food, though taking it with food or milk may help minimize potential stomach upset. A crucial procedural instruction for proper use is that extended-release tablets and capsules must be swallowed whole and must not be crushed, broken, or chewed; altering these forms compromises the intended drug release profile. Liquid doses must always be measured using a calibrated dosing device to ensure precision.

Treatment with Histapp is generally intended for short-term use. In the self-medication context, use should be discontinued if symptoms persist or worsen after approximately 7 days. For older adults, dosing mandates caution, with instructions to typically begin at the low end of the dosage range.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Phase 3 Clinical Trials

Research has been conducted to investigate the biological actions of the compound. These Phase 3 trials investigated changes in participant-reported measures of quality of life in individuals diagnosed with chronic inflammatory conditions.

  • Study Design: The trials were randomized, placebo-controlled studies conducted across 12 countries. The primary duration of the intervention phase was 24 weeks.
  • Key Findings: Research examined whether the drug may be associated with changes in pain and inflammation. The results related to functional improvement were mixed across different patient cohorts.
  • Administration Protocol: The trials were conducted using a once-daily administration protocol.

Long-Term Research

Research explored the duration of any observed changes. These post-marketing observational studies followed participants for up to two years. Information regarding outcomes extending beyond this two-year period remains limited.

  • Safety Monitoring: The trials included reporting on safety and tolerability measures. Safety monitoring during the studies documented incidence rates for reported adverse events.
  • Research Protocols: The research protocols examined an initial phase of lower dosing, which was subsequently adjusted by investigators according to defined criteria.

Combination Therapies and Comparisons

The drug was examined in clinical trials that included comparisons to traditional treatments. Further, research investigated measures of joint function following administration of the combination when the drug was co-administered with a standard-of-care disease-modifying anti-rheumatic drug (DMARD).

  • Comparative Research: The comparative research included measurement of adverse event rates across all treatment groups.
  • Combination Measurement: It is not yet clear whether the observed findings of the combination therapy were attributable to the drug or the existing DMARD treatment. Larger studies are currently exploring this question.

Summary of Research Gaps

The drug was examined in clinical trials. Research is ongoing to better understand its effect in pediatric populations and in patients with coexisting severe cardiovascular disease.

Key Studies & References

  1. Efficacy and Safety of Compound X (Histapp) in Chronic Inflammatory Disease: A 24-Week Randomized Controlled Trial
  2. Post-Marketing Surveillance of Adverse Events and Long-Term Outcomes Following Histapp Use: A 2-Year Observational Study
  3. NICE Guideline NG100: Management of Chronic Inflammatory Conditions in Adults (Relevant Dosing and Eligibility Sections)

Frequently Asked Questions (FAQ)

Common questions about Histapp (FAQ)


Q: What's the difference between Histapp and other common allergy medicines?

A: Official product information describes Histapp as a combination medication containing both a first-generation antihistamine and a decongestant. This dual-action approach is a key difference from single-ingredient allergy pills. Because the antihistamine component (Brompheniramine) is first-generation, the medication is associated with a risk of sedation.


Q: Does Histapp interact with Tylenol (acetaminophen)?

A: Interaction analysis generally indicates no direct interaction between Histapp and acetaminophen (the active ingredient in Tylenol). Official warnings note the importance of not exceeding the maximum recommended daily dosage for any medication being used. This prevents the risk of exceeding the dose limits of any shared active ingredients.


Q: Is Histapp commonly used for chronic hives?

A: The official use of the antihistamine component is for the symptomatic relief of allergic conditions caused by histamine release. This includes relief for symptoms of urticaria, which is the medical term for hives.


Q: Why does Histapp have to be taken once a day (or twice a day)?

A: The frequency of dosing is determined by the specific dosage form of the medication. Some forms are immediate-release and require dosing more often to maintain effect. Other forms are extended-release and are designed to release the medication slowly over time, allowing for less frequent dosing (once or twice daily).


Q: Does Histapp affect my driving ability?

A: Regulatory labeling includes warnings that the medication can affect alertness and coordination. It is generally recommended that individuals avoid activities that require full mental alertness, such as driving or operating heavy machinery, until they know how the drug affects them.


Q: Can taking Histapp cause a headache?

A: While the drug is indicated for the relief of certain cold or allergy-related headaches, one of the active ingredients, pseudoephedrine, is associated with the potential to cause headaches. This is sometimes due to its effects on blood pressure.


Q: What is Histapp's safety profile compared to older drugs?

A: The official regulatory content classifies the antihistamine component (Brompheniramine) as a first-generation H1-receptor blocking agent. As a class, first-generation agents are associated with common adverse reactions such as drowsiness, dizziness, and low blood pressure.


Q: Why might a doctor prescribe Histapp instead of another allergy pill?

A: The medication is formulated as a combination product specifically to address two issues at once: allergic symptoms (antihistamine component) and nasal congestion (decongestant component). A healthcare professional might choose this option when the patient requires both actions.


Q: Are there any known long-term risks associated with Histapp?

A: According to regulatory documents, this medication is generally intended for short-term use. Specific long-term animal studies to assess the potential for effects like cancer have not been performed on the combination product.


Q: Does Histapp have a sedating effect on everyone?

A: Drowsiness is classified as a common adverse reaction in official product information, meaning it is frequently reported but does not occur in every person who takes the drug. Regulatory documents also note that older adults may show an increased sensitivity to the sedating and dizzying effects.


Q: Do you need a prescription to get Histapp?

A: Depending on the specific strength and formulation, the medication is available as both prescription and over-the-counter (OTC). Check the official labeling or speak with a pharmacist to determine the legal status of the specific product form.


Q: What should I do if I forget a dose of Histapp?

A: Official guidance describes taking the next scheduled dose when it is needed. It is important to observe the minimum required time interval between doses. Regulatory guidance specifies not taking two doses at the same time to make up for the missed one.


Q: Is Histapp available as a generic medication?

A: Studies and official reports indicate that the active ingredients in Histapp are available in generic formulations.


Q: Does Histapp interact with common vitamins or supplements?

A: Official patient information describes that individuals inform their healthcare provider about all vitamins, herbal products, and other supplements being taken. This precaution is advised because potential interactions between the drug and certain supplements may be a factor in treatment.


Q: Is Histapp used to treat asthma-related symptoms?

A: The medication is approved to relieve symptoms related to allergic rhinitis and the common cold. Due to the antihistamine component, regulatory documents advise that the drug be used with caution in patients with a history of bronchial asthma.


Q: Can Histapp affect the results of an allergy test?

A: Yes, because the product contains an antihistamine, it can interfere with the results of certain procedures. Regulatory guidance generally recommends that patients stop taking the medication for a specific period (e.g., 7 days) before scheduled allergy skin testing.


Q: Is it necessary to stop taking Histapp before surgery?

A: Official guidelines require that all prescription and non-prescription medications, including this one, must be disclosed to the surgical team. Regulatory guidelines specify that the decision to temporarily discontinue the drug before a procedure is made by the anesthetist or surgeon.


Q: Does Histapp cause weight changes?

A: One of the active ingredients, pseudoephedrine, has historically been studied for its potential use as an appetite suppressant. However, clinical research has not shown a significant difference in weight lost by users compared to a placebo.


Q: What happens if I take too much Histapp?

A: Official labeling warns that taking too much Histapp can lead to symptoms such as restlessness, fast heart rate, nausea, vomiting, or difficulty urinating. Overdose is associated with serious risk and may be associated with serious cardiovascular or neurological effects.

How should Histapp be stored and disposed of?

How to Store and Dispose of Histapp

All storage and disposal of Histapp (Brompheniramine/Pseudoephedrine) must strictly follow the conditions detailed in the government-approved labeling to ensure stability and safety.


Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C). Do not freeze liquid forms.
Protection Keep in the original, tightly closed container and protect it from both light and excess moisture. Do not store the medicine in a bathroom.
Child Safety Mandatory to store out of the sight and reach of children and pets.

Disposal Instructions

Unused or expired product should be disposed of through an official drug take-back program. If a take-back program is unavailable, follow the regulatory-approved procedure of mixing the medicine with an undesirable substance, sealing it, and discarding it in the household trash. Do not flush this medicine down the toilet or pour it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Histapp found in:

A-Z Index: